Beating Merck, Pfizer gets priority review as the first Prevnar follow-up heads to the FDA
It won’t get quite the work-on-Thanksgiving welcome that the Covid-19 jab received, but another Pfizer vaccine is headed to the FDA, where it will receive a speedy review.
Pfizer announced Wednesday that an application for its new pneumococcal vaccine, 20vPnC, has been accepted and granted priority review at the agency, setting up a decision by June of next year.
With the acceptance, Pfizer remains a step ahead of Merck in the race to develop a follow-on to one of the Big Pharma’s most important profit generators. While most vaccines are slim margin product, Prevnar collected $6 billion in revenue last year, more than any other fully owned Pfizer product.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters